Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Open-label, Multicenter, Long-term Study to Evaluate the Safety and Efficacy of TAK-536, Amlodipine and Hydrochlorothiazide in Subjects With Essential Hypertension

NCT02277691 is registered in ClinicalTrials.gov with Takeda as lead sponsor.

NCT NCT02277691
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02277691 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Open-label, Multicenter, Long-term Study to Evaluate the Safety and Efficacy of TAK-536, Amlodipine and Hydrochlorothiazide in Subjects With Essential Hypertension
Lead sponsor
Takeda
Phase
Phase 3
Overall status
Completed
Start date
November 7, 2014
Completion date
April 25, 2016
Enrollment
341 (actual)
Sites
38

Conditions

As the registry lists them; a condition with its own page is linked.

essential hypertension